DK1250146T3 - Anvendelse af botulinumtoxin til behandling af diabetes - Google Patents

Anvendelse af botulinumtoxin til behandling af diabetes

Info

Publication number
DK1250146T3
DK1250146T3 DK01903262T DK01903262T DK1250146T3 DK 1250146 T3 DK1250146 T3 DK 1250146T3 DK 01903262 T DK01903262 T DK 01903262T DK 01903262 T DK01903262 T DK 01903262T DK 1250146 T3 DK1250146 T3 DK 1250146T3
Authority
DK
Denmark
Prior art keywords
diabetes
treatment
botulinum toxin
botulinum
toxin
Prior art date
Application number
DK01903262T
Other languages
English (en)
Inventor
Stephen Donovan
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DK1250146T3 publication Critical patent/DK1250146T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/832—Drug, bio-affecting and body treating compositions involving bacterial toxin that has modified amino acid sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK01903262T 2000-01-26 2001-01-24 Anvendelse af botulinumtoxin til behandling af diabetes DK1250146T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/491,420 US6337075B1 (en) 2000-01-11 2000-01-26 Methods for treating diabetes
PCT/US2001/002273 WO2001054711A2 (en) 2000-01-26 2001-01-24 Use of neurotoxins for treating diabetes

Publications (1)

Publication Number Publication Date
DK1250146T3 true DK1250146T3 (da) 2004-04-26

Family

ID=23952146

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01903262T DK1250146T3 (da) 2000-01-26 2001-01-24 Anvendelse af botulinumtoxin til behandling af diabetes

Country Status (11)

Country Link
US (2) US6337075B1 (da)
EP (1) EP1250146B1 (da)
JP (1) JP4851042B2 (da)
AR (1) AR029464A1 (da)
AT (1) ATE257013T1 (da)
AU (1) AU2001231104A1 (da)
DE (1) DE60101669T2 (da)
DK (1) DK1250146T3 (da)
ES (1) ES2211765T3 (da)
TW (1) TWI233806B (da)
WO (1) WO2001054711A2 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6261572B1 (en) * 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US6337075B1 (en) 2000-01-11 2002-01-08 Allergan Sales, Inc. Methods for treating diabetes
US8632785B2 (en) 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
EP1398038B2 (en) * 2000-02-08 2011-01-26 Allergan, Inc. Botulinum toxin pharmaceutical compositions
US7780967B2 (en) 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20030118598A1 (en) 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US6492339B1 (en) * 2001-05-23 2002-12-10 Insmed, Incorporated Compositions comprising D-chiro inositol and sulfonylureas and methods of treatment thereof
US6486127B1 (en) * 2001-05-23 2002-11-26 Insmed, Incorporated Compositions comprising D-chiro inositol and lipid lowering compounds and methods of treatment thereof
US6984375B2 (en) * 2001-08-03 2006-01-10 Allergan, Inc. Nuclei density and nuclei area methods for determining effects of a botulinum toxin on muscles
CA2466697C (en) 2001-11-15 2013-09-24 Micro Algae Corporation Pharmaceutical compositions containing 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
EP1802250A4 (en) * 2004-05-07 2008-07-02 Phytotox Ltd METHOD FOR TREATING WOUNDS WITH GONYAUTOXINES
EP1796676B1 (en) * 2004-05-07 2016-03-09 Phytotox Limited Transdermal administration of phycotoxins
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
WO2006130161A2 (en) * 2004-07-21 2006-12-07 The Cornell Research Foundation, Inc. Therapeutic compounds derived from spider venom and their method of use
AU2005279741B2 (en) 2004-09-01 2011-10-06 Allergan, Inc. Degradable clostridial toxins
WO2006101809A1 (en) 2005-03-15 2006-09-28 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
US8105611B2 (en) * 2005-06-17 2012-01-31 Allergan, Inc. Treatment of autoimmune disorder with a neurotoxin
WO2009002437A2 (en) * 2007-06-25 2008-12-31 The Board Of Regents Of The University Of Texas System Neurotoxin theraphy for postprandial hyperglycemia
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
FR2972928B1 (fr) * 2011-03-25 2013-11-29 Urgo Lab Composition contenant une cellulose, une huile vegetale et un solvant volatil, ses utilisations comme pansement
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
WO2016110662A1 (en) 2015-01-09 2016-07-14 Ipsen Bioinnovation Limited Cationic neurotoxins
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
JP7118055B2 (ja) 2016-09-29 2022-08-15 イプセン バイオファーム リミテッド ハイブリッド神経毒
US20210187194A1 (en) 2018-02-26 2021-06-24 Ipsen Biopharm Limited Use of Ultrasound to Guide Injection of Non-cytotoxic Protease
US10960061B1 (en) 2019-10-18 2021-03-30 Penland Foundation Treatment of amyotrophic lateral sclerosis using botulinum toxin
US10967052B1 (en) 2019-10-18 2021-04-06 Penland Foundation Treatment of dyslexia using botulinum toxin
US20220143158A1 (en) * 2020-09-18 2022-05-12 Vanderbilt University Duodenal administration of botulinum toxin
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
WO2023287729A1 (en) 2021-07-12 2023-01-19 Penland Foundation Treatment of acute and chronic kidney disease
WO2023287728A1 (en) * 2021-07-12 2023-01-19 Penland Foundation Treatment of diabetes and chronic pancreatitis using botulinum toxin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
EP1147776B1 (en) 1993-12-28 2010-12-15 Allergan, Inc. Use of botulinum toxin type B for the manufacture of a medicament for the treatment of muscle spasms
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
ES2198484T3 (es) 1995-06-06 2004-02-01 L. Bruce Pearce Composiciones y procedimientos mejorados para quimiodenervacion usando neurotoxinas.
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6261572B1 (en) * 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US6143306A (en) * 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6337075B1 (en) 2000-01-11 2002-01-08 Allergan Sales, Inc. Methods for treating diabetes

Also Published As

Publication number Publication date
AR029464A1 (es) 2003-07-02
ATE257013T1 (de) 2004-01-15
JP4851042B2 (ja) 2012-01-11
EP1250146B1 (en) 2004-01-02
DE60101669D1 (de) 2004-02-05
US6416765B1 (en) 2002-07-09
US6337075B1 (en) 2002-01-08
TWI233806B (en) 2005-06-11
ES2211765T3 (es) 2004-07-16
AU2001231104A1 (en) 2001-08-07
JP2003520822A (ja) 2003-07-08
WO2001054711A3 (en) 2002-02-21
WO2001054711A2 (en) 2001-08-02
DE60101669T2 (de) 2004-10-21
EP1250146A2 (en) 2002-10-23
US20020031529A1 (en) 2002-03-14

Similar Documents

Publication Publication Date Title
DK1250146T3 (da) Anvendelse af botulinumtoxin til behandling af diabetes
DK1604681T3 (da) Anvendelse af botulinustoksin til behandling af ledsmerte
DK1253932T3 (da) Lægemidler med botulinustoxin
DK1323222T3 (da) Önet og fremgangsmåde til drift af et önet
ATE322251T1 (de) Neurotoxin implantat
BR0105361B1 (pt) artigo absorvente.
BR0100865B8 (pt) artigo absorvente.
BR0103836B1 (pt) artigo absorvente.
DE60106275T8 (de) Dermatologische zusammensetzung
DE60129029D1 (de) Nox-speicher
BR0100151B1 (pt) artigo absorvente.
DE50114713D1 (de) Mikrostrukturbauelement
DK1278416T3 (da) Flydende præparater
BR0100961B1 (pt) artigo absorvente.
BR0102028B1 (pt) artigo absorvente.
BR0113254B1 (pt) dispositivo emagrecedor.
BR0112264B1 (pt) dispositivo de tratamento de sangue.
IS7275A (is) Samsetning fyrir hollegg og notkun á henni
BR0100962B1 (pt) artigo absorvente.
DE10196460T1 (de) Selbstzerstör-Spritze
DK1461042T3 (da) Anvendelse af desoxypeganin til behandling af klinisk depression
BR0107047B1 (pt) artigo absorvente.
DE50109358D1 (de) Flüssigkristall-Anzeige
DK1286669T3 (da) Præparater til forebyggelse af mavesår hos heste
ITMI20022425A1 (it) Distanziatore e distanziale.